Fatal Respiratory Events Caused by Zanamivir Nebulization
To the Editor-GlaxoSmithKline was very concerned to learn of the fatality of a 25-year-old pregnant woman with severe H1N1 influenza A following nebulized administration by means of mechanical ventilation of zanamivir solution, described in the letter by Kiatboonsri et al [1] . This solution had been made by the treating hospital pharmacy from the lactose powder formulation of zanamivir, marketed as Relenza Diskhaler. As highlighted in GlaxoSmithKline's communication to health care professionals, this formulation is not intended to be reconstituted in any liquid formulation for administration by nebulization and is not approved for this use [2] .
GlaxoSmithKline wishes to distinguish between the lactose powder solution administered to the patient described in the letter [1] and the aqueous saline solution of zanamivir that was used in early studies of nebulized zanamivir and that is currently in clinical development for intravenous administration in patients with severe influenza. The aqueous saline solution of zanamivir does not contain lactose, the presumed cause of ventilator occlusion in this case.
The safety and effectiveness of zanamivir aqueous saline solution have not yet been established, and this formulation has not been approved by the US Food and Drug Administration or any other regulatory agency. Limited safety data have not identified safety concerns when this formulation has been administered by means of nebulization to healthy volunteers and subjects hospitalized with influenza, some of whom have received zanamivir aqueous solution by means of nebulization through the global compassionate use program [3, 4] . The company has no information about the administration of nebulized zanamivir aqueous saline solution administered to patients who are undergoing mechanical ventilation.
GlaxoSmithKline strongly discourages nebulization of the lactose powder formulation, which is intended only for oral inhalation by means of Diskhaler as packaged, in accordance with approved product labeling.
Emerging Rickettsioses Reach the United States
The paper by Shapiro et al [1] on the description of a new tick-borne rickettsiosis highlights the dramatic need for more investigators in the field of emerging rickettsioses in the United States. Until the 1970s, the United States was the world leader when it came to describing new species of Rickettsiae, in particular those from ticks [2] . The oversimplification of the clinical diagnoses of rickettsioses as a result of unspecific serological testing has led to the conclusion that all tick-borne rickettsioses in the United States were caused by Rickettsia rickettsii. This conclusion was consistently reported in American reference books [2] and was in contradiction with the finding of many rickettsiae in ticks that earlier investigators suspected were pathogenic, including R. parkeri and R. canadensis [3] . Moreover, evidence of a new genotype of Rickettsia identical to R. parkeri discovered in 1990 among tested "R. rickettsii" human isolates was falsely considered an atypical R. rickettsii genotype despite the genetic evidence [3] . This illustrates the effect of dogma on the study of tick-borne rickettsioses in the United States. Interest in rickettsioses in the United States reappeared in recent years because of the development of many new diagnostic tools (such as polymerase chain reaction) and because of the attention related to the fact that rickettsioses were considered by the Centers for Disease Control and Prevention as possible bioterrorism agents after 11 September 2001; however, the use of Rickettsia for bioterrorism is highly unlikely. Therefore, a considerable increase in the number of declared cases of Rocky Mountain spotted fever was noted, along with a striking decrease in mortality [4] . I suggested that this was a massive diagnostic error, because the number of reported annual cases increased from !700 in 2001 to 2288 in 2006 without any reason [4] . During the same time, fatality rates decreased from 1.4% to 0.7%. This shows that the reported cases of Rocky Mountain spotted fever were indeed very benign.
Over the past 20 years, new pathogenic rickettsiae have been discovered on all continents, which gave rise to the creation of the new field of emerging rickettsioses [2] (Table 1) . For a long time, the absence 
